Fang Li

Fang Li

Auto-generated profile, based on publicly available information

Fang Li

Department of Dermatology and Venereology The First Affiliated Hospital with Nanjing Medical University Nanjing China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
ZLZhihua Li
Zhihua Li
WWWeibing Wu
Weibing Wu
XPXianglong Pan
Xianglong Pan
FLFang Li
Fang Li
QZQuan Zhu
Quan Zhu
LCLiang Chen
Liang Chen
Background: This study aims to reveal the serum tumor marker (STM) levels in lung adenocarcinoma (LUAD) histological subtypes and evaluate their values in predicting the solid and micropapillary components (SMC).Methods: We retrospectively analyzed 3100 invasive LUAD patients between January 2017 and December 2020. Associations between preoperative STMs (CEA, CYFRA21‐1, CA199, CA724, NSE, AFP) and LUAD subtypes were evaluated. Multivariate regression analyses were used to determine the independent predictors. Predictive models for SMC were constructed and AUC (area under the curve) was calculated.Results: CEA and CYFRA21‐1 levels differed across the LUAD histological subtypes, with the SPA (solid‐predominant adenocarcinoma) having the highest level and the LPA (lepidic‐predominant adenocarcinoma) harboring the lowest level (p <0.001). Tumors with SMC also had higher CEA and CYFRA21‐1 levels than those absence of SMC. Gender, tumor size, CEA, Ki‐67, EGFR mutation (solid components only), and tumor differentiation were significantly independently associated with the containing of SMC. Patients were split into two data sets (training set: 2017–2019 and validation set: 2020). The model with gender and tumor size yielded an AUC of 0.723 (training set) and 0.704 (validation set) for the solid component. Combination of CEA, gender, and tumor size led to a significant increase in the predictive accuracy (training set: 0.771, p = 0.009; validation set: 0.747, p = 0.034). The AUC of the model for micropapillary component with only gender and tumor size was 0.699 and 0.711 in the training set and validation set, respectively. Integration of CEA with gender and tumor size significantly improved the predictive performance with an AUC of 0.746 (training set, p = 0.045) and 0.753 (validation set, p <0.001).Conclusion: Serum CEA and CYFRA21‐1 varied considerably according to LUAD histological subtypes. The combination of serum CEA and other factors showed prominent values in predicting the SMC.

19 July 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
FLFang Li
Fang Li
XWXiao‐Qing Wang
Xiao‐Qing Wang
MLMeng‐Xi Liu
Meng‐Xi Liu
HWHoi‐Shiwn Wong
Hoi‐Shiwn Wong
ZLZhen‐Ru Liu
Zhen‐Ru Liu
DWDa‐Guang Wang
Da‐Guang Wang

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
XWXiao-Qing Wang
Xiao-Qing Wang
JJJia-Yi Jiang
Jia-Yi Jiang
MLMeng-Xi Liu
Meng-Xi Liu
ZLZhen-Ru Liu
Zhen-Ru Liu
FLFang Li
Fang Li
DWDaguang Wang
Daguang Wang
Background. Ingrown nails are a type of nonspecific inflammation of nail folds. Intralesional injection is a rarely reported nonsurgical therapy for ingrown nails. Objective. To observe the efficacy of treating ingrown nails with intralesional injection, and to evaluate at which stage ingrown nails are applicable for this therapy. Methods. Ingrown nails were randomly divided into treatment (n = 87) and control (n = 37) groups. The treatment group received local injections combined with basic nursing, whereas the control group was only treated with basic nursing. Patients were followed up at 1 week, 1 month, 3 months, and 6 months after the first treatment. Results. A statistically significant difference of the efficacy rates was observed between the two groups (P < 0.05). The overall satisfaction rate was 83.91% in the treatment group and 64.86% in the control group (P = 0.019). Conclusion. Intralesional injection is an effective therapy for ingrown nails, especially in the short term. This therapy is more applicable for Martinez‐Nova stage I and IIA ingrown nails and can be used as a symptomatic treatment to relieve the acute inflammation of ingrown nails at stages IIB, III, and IV.

29 August 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FLFang Li
Fang Li
JJJia‐Yi Jiang
Jia‐Yi Jiang
SHShu‐Dai Huang
Shu‐Dai Huang
MLMeng‐Xi Liu
Meng‐Xi Liu
XWXiao‐Qing Wang
Xiao‐Qing Wang
DWDaguang Wang
Daguang Wang

28 June 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
JLJuan Liu
Juan Liu
YZYuan Zhou
Yuan Zhou
MLMeng‐Xi Liu
Meng‐Xi Liu
ZLZhen‐Ru Liu
Zhen‐Ru Liu
XWXiao‐Qing Wang
Xiao‐Qing Wang
DWDaguang Wang
Daguang Wang

22 September 2026 in EBioMedicine
Verified
Journal Article
Open access
XFXiaokai Fang
Xiaokai Fang
FLFang Li
Fang Li
YGYuwen Gao
Yuwen Gao
YZYu Zhang
Yu Zhang
XCXingyu Chen
Xingyu Chen
XYXu Yao
Xu Yao